Hiperhomosisteinemia dan Faktor Risiko Kelainan Vaskuler
DOI:
https://doi.org/10.18196/mmjkk.v8i2.1477Keywords:
homocystein, Risk Factor, Vascular Disease, faktor risiko, homosistein, kelainan vaskularAbstract
Homocysteine is a sulfhydryl-containing amino acid derived from the essential amino acid methionine, which is abundant in animal sources of protein. Raised plasma homocysteine (tHcY) concentrations are caused by genetic mutations, vitamin dificiencies, renal and ather diseases, numerous drugs and increasing age. Raised tHcY concentrations are associated with laboratory evidence of atherothrombotic. In experimental studies, homocysteine causes oxidative stress, damages endothelium, and enhances thrombogenicity. Epidemiological studies have shown that too much homocysteine in the blood (plasma) is related to a higher risk of coronary heart disease, stroke and peripheral vascular disease. Supplementation of folic acid with vitamin B6 and Bn combination can be lowering homocysteine. There is currently insufficient evidence to recommend routine screening and treatment of high tHcy concentrations with folic acid and other vitamins to prevent atherothrombotic vascular disease. There is the discordance between the epidemiology of homocysteine and the results of the clinical trials.
Homosistein adalah asam amino sulfhydril, merupakan senyawa antara yang terbentuk dalam metabolisme asam amino esensial metionin, banyak berasal dari protein hewani. Peningkatan homosistein disebabkan oleh mutasi genetik, defisiensi vitamin, penyakit ginjal dan penyakit lain, obat-obatan dan peningkatan usia. Peningkatan kadar homosistein menyebabkan aterotrombosis. Homosistein menyebakan stress oksidatif, kerusakan endotel (disfungsi endotel) dan memacu trombosis. Studiepidemiologimemperlihatkan peningkatan homosistein plasma beihubungan dengan kejadian penyakit jantung koroner, stroke dan penyakit pembuluh darah perifer. Pemberian suplemen asam folat dengan kombinasi vitamin B6 danvitaminB12 menurunkan kadar homosistein. Buktiyang kuat untuk memberikan asam folat atau vitamin lainnya secara rutin maupun dalam terapi untuk pencegahan penyakit aterotrombosis belum didapatkan. Terdapat ketidaksesuaian antara studi epidemiologi dan clinical trial.
References
Alexander, R. Wayne, 1994. The Heart Arteries and Veins. Volumel. 8th edition. McGraw Hill Press. USA
Wijaya, Andi, 1998. Faktor Risiko Penyakit Kardiovaskular Perspektif Baru Dalam Forum Diagnosticum. No2/1998. Lab. Prodia Jakarta
Http://www.americanheart.ora/
Bolander-Gouaille, C. 2002. Focus on Homocysteine and the Vitamins: involved in its metabolism, second enlarged et revised edition, Spinger.
Mallinow, M.R., Bostom.A.G., Krauss, R.M., 1999. AHA Science Advisory: Homocystein, Diet and Cardiovascular disease. Circulation 99:178-182.
Malinow MR., 1990. Hyperhomocystenemia: a common and easily reversible risk factor for artery occlusive atherosclerosis. Circulation ;81:2004-6
Kang, SS.1992. Hyperhomocysteinemia is as a risk Factor for Occlusive vascular disease. Annual Review of Nutrition 12:279-298
Refsum, H., Smith, D., Ueland, P.M., Nexo, E., Clarke, R., McParthin, J., Johnston, C., Engbaek, F., Scneede, J., Scott, J.M., 2004. Facts and Recomendations about Total Homocysteine Determinations; An Expert Opinion. Clinical Chemistry. Vol: 50 No 1
Heijer, M., Koster, T., Blom, H.J., Reitsma, P.H., Vandebroucke, J.P., Rosendall, F.R., 1996. Hyperhomocysteinemia as risk factor for Deep -Vein Thrombosis. NEJM. No 334:759-62
Fonseca, V., Guba, S.C., Fink, L.M.., 1999. Hyperhomocysteinemia and The Endocrine System: Implication for atherosclerosis an Thrombosis. Endocr Rev 49:147-52
Solomon, B.P., Duda, C.T., 1998. Homocysteine Determination in Plasma Current Separation. 17: 1-7
Alpert, M.A., 1999. Homocystein, Atherosclerosis an Thrombosis. Southern Medical J 92:858-865
Graeme, G.J., Eikelboom, J.W., Wai, K.H., Bockxmeer, F.M., 2004. Clinical usefulness of Plasma Homocystein in Vascular disease. MJA. 181:314-318.
Welch G.N., Loscalzo, J., 1998. Homocysteinemia and Atherothrombosis: Review Article . NEJM 338:1042-1050.
Hankey, G., Eikelboom, J.W., 1999. Homocysteine and vascular disease. The Lancet 354: 407-413
Harpel, PC., Zhang, X., Borth, W., 1996. Homocysteine and Hemostasis; Pathogenetic Mechanism Predisposing to Thrombosis. J. Nutr. 126:1285-9
Topol, Eric, J., 2002. Text Book of Cardiovascular Medicine. 2nd edition. Lippincot & Wilkins Press. Philadelphia
David, S.W., Malcom W., Joan, K.M. 2002. Homocysteine and Cardiovascular Disease: Evidence on Causality from a Meta-analysis. British Medical Journal 2002;325(7374): 1202
Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202- 1206.
Ueland, PM, Refsum, H., Stabler, S.P. 1993. Total Homoysteine in Plasma or Serum Methods and clinical Aplication. Clin Chem 39: 1764-79
The Centers for Disease Control and Prevention. 1999. Assesment of Laboratory Test for Plasma Homocysteine-Selected Laboratories, Jully-September 1998. JAMA. 282:2112-3
Joubran, R., Asmi, M., Law, T., Spencer, A., 2000. Agreement among Four Homocysteine Assays and Results in Patients with Coronary Atherosclerosis and Controls. Clinical Chemistry: 46: 258-64
Manuel R, Malinow, Paul B. Duell, David LD., 1998. Reduction of Plasma Homocysteine Levels by Breakfast Cereal Fortified with Folic Acid in Patients with Coronary Heart Disease. N Engl J, volume 338: 1009-15
Petersen, JC., Spence, J.D., 1998. Vitamins and Progression of Atherosclerosis in Hyper-homocysteinemia. Lancet 351:263
Brattstrom, L., Cuskelly, 1998. Homocysteine Lowering Trialist Collaboration Lowering Blood Homocysteine with FolicAcid based Supplements:Meta-analysis of Randomized Trial. British Medical Journal 316:984-898.
Bonaa K.H., Njolstad I., Ueland P.M., Schirmer H., Tverdal A., Steigen T., Wang H., Nordrehaug J.E., Arnesen E., and Rasmussen K., 2006. Homocysteine Lowering and CardiovascularEvents after Acute Myocardial Infarction. N Engl J Med ;354.
Downloads
Published
Issue
Section
License
Copyright
Authors retain copyright and grant Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK) the right of first publication with the work simultaneously licensed under an Attribution 4.0 International (CC BY 4.0) that allows others to remix, adapt and build upon the work with an acknowledgment of the work's authorship and of the initial publication in Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK).
Authors are permitted to copy and redistribute the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK).
License
Articles published in the Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK) are licensed under an Attribution 4.0 International (CC BY 4.0) license. You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
This license is acceptable for Free Cultural Works. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
